Are ketogenic diets promising for Alzheimer's disease? A translational review.
Alzheimer’s disease
Animal models
Brain metabolism
Ketogenic diet
Journal
Alzheimer's research & therapy
ISSN: 1758-9193
Titre abrégé: Alzheimers Res Ther
Pays: England
ID NLM: 101511643
Informations de publication
Date de publication:
14 04 2020
14 04 2020
Historique:
received:
07
01
2020
accepted:
02
04
2020
entrez:
16
4
2020
pubmed:
16
4
2020
medline:
23
6
2021
Statut:
epublish
Résumé
Brain amyloid deposition and neurofibrillary tangles in Alzheimer's disease (AD) are associated with complex neuroinflammatory reactions such as microglial activation and cytokine production. Glucose metabolism is closely related to neuroinflammation. Ketogenic diets (KDs) include a high amount of fat, low carbohydrate and medium-chain triglyceride (MCT) intake. KDs lead to the production of ketone bodies to fuel the brain, in the absence of glucose. These nutritional interventions are validated treatments of pharmacoresistant epilepsy, consequently leading to a better intellectual development in epileptic children. In neurodegenerative diseases and cognitive decline, potential benefits of KD were previously pointed out, but the published evidence remains scarce. The main objective of this review was to critically examine the evidence regarding KD or MCT intake effects both in AD and ageing animal models and in humans. We conducted a review based on a systematic search of interventional trials published from January 2000 to March 2019 found on MEDLINE and Cochrane databases. Overall, 11 animal and 11 human studies were included in the present review. In preclinical studies, this review revealed an improvement of cognition and motor function in AD mouse model and ageing animals. However, the KD and ketone supplementation were also associated with significant weight loss. In human studies, most of the published articles showed a significant improvement of cognitive outcomes (global cognition, memory and executive functions) with ketone supplementation or KD, regardless of the severity of cognitive impairments previously detected. Both interventions seemed acceptable and efficient to achieve ketosis. The KD or MCT intake might be promising ways to alter cognitive symptoms in AD, especially at the prodromal stage of the disease. The need for efficient disease-modifying strategies suggests to pursue further KD interventional studies to assess the efficacy, the adherence to this diet and the potential adverse effects of these nutritional approaches.
Sections du résumé
BACKGROUND
Brain amyloid deposition and neurofibrillary tangles in Alzheimer's disease (AD) are associated with complex neuroinflammatory reactions such as microglial activation and cytokine production. Glucose metabolism is closely related to neuroinflammation. Ketogenic diets (KDs) include a high amount of fat, low carbohydrate and medium-chain triglyceride (MCT) intake. KDs lead to the production of ketone bodies to fuel the brain, in the absence of glucose. These nutritional interventions are validated treatments of pharmacoresistant epilepsy, consequently leading to a better intellectual development in epileptic children. In neurodegenerative diseases and cognitive decline, potential benefits of KD were previously pointed out, but the published evidence remains scarce. The main objective of this review was to critically examine the evidence regarding KD or MCT intake effects both in AD and ageing animal models and in humans.
MAIN BODY
We conducted a review based on a systematic search of interventional trials published from January 2000 to March 2019 found on MEDLINE and Cochrane databases. Overall, 11 animal and 11 human studies were included in the present review. In preclinical studies, this review revealed an improvement of cognition and motor function in AD mouse model and ageing animals. However, the KD and ketone supplementation were also associated with significant weight loss. In human studies, most of the published articles showed a significant improvement of cognitive outcomes (global cognition, memory and executive functions) with ketone supplementation or KD, regardless of the severity of cognitive impairments previously detected. Both interventions seemed acceptable and efficient to achieve ketosis.
CONCLUSION
The KD or MCT intake might be promising ways to alter cognitive symptoms in AD, especially at the prodromal stage of the disease. The need for efficient disease-modifying strategies suggests to pursue further KD interventional studies to assess the efficacy, the adherence to this diet and the potential adverse effects of these nutritional approaches.
Identifiants
pubmed: 32290868
doi: 10.1186/s13195-020-00615-4
pii: 10.1186/s13195-020-00615-4
pmc: PMC7158135
doi:
Types de publication
Journal Article
Review
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
42Références
Int J Biochem Cell Biol. 2015 Jun;63:55-9
pubmed: 25666556
Curr Alzheimer Res. 2013 Mar;10(3):290-7
pubmed: 23131121
Expert Opin Investig Drugs. 2017 Jun;26(6):735-739
pubmed: 28460541
Nutrients. 2019 Apr 26;11(5):
pubmed: 31035514
J Neurochem. 2017 Apr;141(2):195-207
pubmed: 28099989
J Gerontol A Biol Sci Med Sci. 2018 Mar 14;73(4):450-458
pubmed: 29040389
Nutr Metab (Lond). 2005 Oct 17;2:28
pubmed: 16229744
Nutrients. 2018 Sep 20;10(10):
pubmed: 30241310
Alzheimers Dement. 2019 May;15(5):625-634
pubmed: 31027873
Neurobiol Aging. 2013 Jun;34(6):1530-9
pubmed: 23276384
Clin Interv Aging. 2016 Jan 08;11:29-36
pubmed: 26811674
Psychopharmacology (Berl). 2016 Oct;233(21-22):3797-3802
pubmed: 27568199
Nutrition. 2019 Apr;60:118-121
pubmed: 30554068
Curr Neuropharmacol. 2009 Sep;7(3):257-68
pubmed: 20190967
Neurology. 2010 Aug 31;75(9):764-70
pubmed: 20739649
PLoS Med. 2009 Jul 21;6(7):e1000097
pubmed: 19621072
Antioxid Redox Signal. 2012 Jun 15;16(12):1434-55
pubmed: 21902597
Nutr Metab (Lond). 2009 Aug 10;6:31
pubmed: 19664276
Exp Gerontol. 2018 Oct 1;111:118-121
pubmed: 30006299
J Neurosci Res. 2006 Mar;83(4):702-9
pubmed: 16435389
J Alzheimers Dis. 2015;43(4):1343-53
pubmed: 25147107
Neurosci Lett. 2019 Jan 18;690:232-236
pubmed: 30367958
Nutrients. 2018 Nov 07;10(11):
pubmed: 30405021
PLoS One. 2016 Aug 12;11(8):e0160159
pubmed: 27517611
Brain Res. 2013 Apr 10;1505:61-7
pubmed: 23415649
J Nutr Sci Vitaminol (Tokyo). 2017;63(2):133-140
pubmed: 28552878
Nutrients. 2018 May 25;10(6):
pubmed: 29799502
Exp Neurol. 2011 Dec;232(2):195-202
pubmed: 21939657
Front Neurol. 2018 Feb 12;9:64
pubmed: 29483892
FASEB J. 2005 Apr;19(6):659-61
pubmed: 15650008
BBA Clin. 2015 Jan 16;3:123-5
pubmed: 26675661
Brain Res Bull. 2012 May 1;88(1):3-12
pubmed: 22142973
Proc Natl Acad Sci U S A. 2000 May 9;97(10):5440-4
pubmed: 10805800
Alzheimer Dis Assoc Disord. 2018 Oct-Dec;32(4):298-304
pubmed: 30188355
Ann Neurol. 2006 Aug;60(2):223-35
pubmed: 16807920
Arch Intern Med. 2006 Feb 13;166(3):285-93
pubmed: 16476868
Neurobiol Aging. 2012 Feb;33(2):425.e19-27
pubmed: 21130529
Neurobiol Aging. 2004 Mar;25(3):311-4
pubmed: 15123336
Curr Opin Neurol. 2017 Apr;30(2):187-192
pubmed: 28141738
Br J Nutr. 2010 Jun;103(12):1746-54
pubmed: 20141643
Cochrane Database Syst Rev. 2018 Nov 07;11:CD001903
pubmed: 30403286
Genes Nutr. 2014 May;9(3):393
pubmed: 24643340
Cardiovasc Diabetol. 2016 Jan 22;15:12
pubmed: 26800892
Cell Metab. 2017 Sep 5;26(3):547-557.e8
pubmed: 28877458
PLoS One. 2013 Sep 12;8(9):e75713
pubmed: 24069439
Front Aging Neurosci. 2018 Dec 03;10:391
pubmed: 30559660
Alzheimers Dement (N Y). 2017 Dec 06;4:28-36
pubmed: 29955649
Nutrients. 2019 Jan 15;11(1):
pubmed: 30650523
Front Mol Neurosci. 2016 Jul 08;9:53
pubmed: 27458340